How OncoVue® Works

The OncoVue® Breast Cancer Risk Test helps a woman put her risk into perspective by predicting the chance of developing breast cancer at different stages throughout her lifetime so she can take a more pro-active approach to breast care.

OncoVue® was developed based on a large and ongoing study of women who have been diagnosed with breast cancer and women who have never been diagnosed with any form of cancer. InterGenetics extensive and growing study includes over 6796 women. Of these, 2235 have breast cancer and 4561 are cancer free. In addition to looking at variations in many genes influencing the average woman's breast cancer risk, some personal medical and family history measures from the National Cancer Institute's Breast Cancer Risk Assessment Tool, as well as others indicated in our studies and other published studies have been examined in our studies.

The OncoVue® test is built upon InterGenetics® proprietary technology platform called "CombiSNP®". A "SNP" is a small inherited change in the DNA in a person's genes. It is not the mere presence of these SNPs that increases cancer risk but certain combinations of SNPs occurring together that increase and decrease the likelihood of developing cancer.

InterGenetics® has identified combinations that predispose individuals to cancer. This platform is the basis for its development of predisposition tests for nearly all forms of cancer - including breast, ovarian, colon, prostate, lung, brain and kidney.

OncoVue® is unlike other risk tests on the market today because it was created for the average woman, not just the small percentage of women with a strong family history that inherit mutations in genes such as BRCA1 and BRCA2. Rather, OncoVue® looks at common variations in many genes involved in growth factors, DNA repair, steroid hormone metabolism, DNA repair, free radical scavenger, and cell cycle control. In other words, there are many important factors that interact to contribute to a person's susceptibility to developing breast cancer. OncoVue® Breast Cancer Risk Test identifies those at risk of developing sporadic breast cancer rather than hereditary breast cancer making the test ideal for women without a strong family history of breast cancer. Even if a woman finds out she's at high risk; it doesn't necessarily mean other members of her family will receive similar results. Each person's risk is unique based on their genetics and personal medical and family history.

OncoVue® will estimate a woman's individual risk and place women in standard, moderate, or high risk groups relative to the average risk for women of their age. One of the interesting features of the OncoVue® test is that the results will give women a score at different stages in her life. Her risk level could change dramatically before or after menopause based on inherited genetic variations.

The OncoVue® results will help a woman and her physician decide if more frequent exams and/or more sophisticated surveillance techniques (which lead to earlier detection and ultimately long term survival) are indicated. Women at higher risk may want to consider preventative treatment options such as Tamoxifen. By knowing her risk, a woman can impact her future through a customized program for preventative treatments, earlier detection, and lifestyle changes developed with the help of her healthcare provider.